Zydus Lifesciences Announces 31st AGM on August 11, 2026, Recommends ₹1 Dividend
Zydus Lifesciences will hold its 31st AGM on August 11, 2026, via VC/OAVM. The company recommended a dividend of ₹1 per share for FY26, payable to shareholders of record on July 24, 2026. Members must update KYC and email details by July 22, 2026.
The AGM and dividend announcement are important for shareholders, impacting their rights and potential returns. The recommended dividend is a key financial detail.
The announcement is a routine disclosure regarding the AGM and dividend recommendation, with no significant positive or negative financial news.
Zydus Lifesciences Limited has announced its 31st Annual General Meeting (AGM) will be held on Tuesday, August 11, 2026, at 10:00 am IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM), in compliance with Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI) circulars.
The company will send its Integrated Report for the Financial Year 2025-26 along with the AGM notice. This will be distributed via email to members with registered email addresses and through a letter providing a web link to the report for those without registered emails. The report and notice will also be available on the company's website and the websites of the stock exchanges.
Members are advised to update their email addresses with MUFG Intime India Private Limited (the Company's RTA) or follow their respective Depository Participant (DP) procedures. Detailed instructions for attending the AGM via VC/OAVM and for e-voting are provided in the notice.
The Board of Directors has recommended a dividend of ₹1 per equity share (100%) for the Financial Year ended March 31, 2026, subject to member approval at the AGM. The dividend, if declared, will be paid to members registered on Friday, July 24, 2026 (Record Date). Dividend income is taxable, and the company will deduct tax at source (TDS) at prescribed rates.
Members holding shares in physical mode are required to update their KYC details by Wednesday, July 22, 2026, to receive dividends electronically. Those holding shares in dematerialized mode should update their bank account details with their respective DP.
What to do with a filing like this
Zydus Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zydus Lifesciences Limited. Read the original for the full detail.